A St. Gallen SME is shaking up the medtech market. The next big step could be a stock exchange listing.
Icotec produces implants for the spine of cancer patients. The products are selling extremely well in the USA. Interested buyers are contacting the company, but the owner family insists on remaining independent.
Icotec, a medical technology company from Altstätten in eastern Switzerland, has achieved rapid growth, increasing its revenue from $8 million in 2019 to $50 million in 2025, with projected earnings of $70 million for this year and nearly $100 million by 2027. The company specializes in producing implants for spinal cancer patients, made from carbon-reinforced plastic, which it believes will replace titanium as the standard material.
Icotec's products have gained significant traction in the US market, with over 80% of its revenue coming from there. The company's growth has attracted interest from potential buyers, but the owning family has emphasized its independence.
Written by urgent.news from NZZ Wirtschaft's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
